Haleos Labs Limited (NSE:HALEOSLABS)

India flag India · Delayed Price · Currency is INR
1,278.40
+15.40 (1.22%)
At close: Mar 9, 2026
9.72%
Market Cap 3.86B
Revenue (ttm) 3.48B
Net Income (ttm) 198.49M
Shares Out 3.02M
EPS (ttm) 65.65
PE Ratio 19.47
Forward PE n/a
Dividend 1.50 (0.12%)
Ex-Dividend Date Sep 24, 2025
Volume 541
Average Volume 772
Open 1,250.00
Previous Close 1,263.00
Day's Range 1,250.00 - 1,300.00
52-Week Range 989.05 - 1,680.00
Beta 0.15
RSI 50.80
Earnings Date Feb 11, 2026

About Haleos Labs

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesci... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1990
Employees 592
Stock Exchange National Stock Exchange of India
Ticker Symbol HALEOSLABS
Full Company Profile

Financial Performance

In fiscal year 2025, Haleos Labs's revenue was 3.45 billion, an increase of 12.67% compared to the previous year's 3.06 billion. Earnings were 201.09 million, an increase of 121.15%.

Financial Statements

News

There is no news available yet.